Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 5/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 5/20 | 0.33 |
| ▸ | BCHE | P06276 | 3/20 | 0.33 |
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.31 |
| ▸ | TNK1 | Q13470 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27031161 | 0.96 | CRBN (0.35) | DDB1CRBNBCHEACHESLC6A4 | |
| Hydrochloric Acid SCHEMBL27031217 | 0.95 | CRBN (0.35) | DDB1CRBNBCHEACHESLC6A4 | |
| SCHEMBL27031141 | 0.93 | EED (0.37) | DDB1CRBNBCHEACHEPARP1 | |
| SCHEMBL27031155 | 0.90 | CRBN (0.34) | DDB1CRBNBCHEACHESLC6A4 | |
| SCHEMBL27031124 | 0.86 | CRBN (0.36) | DDB1CRBNBCHEACHE | |
| SCHEMBL27031149 | 0.86 | DDB1 (0.37) | DDB1CRBNBCHEACHESLC6A4 | |
| SCHEMBL27031113 | 0.85 | ACHE (0.37) | BCHEACHESLC6A4HTR1ACYP2D6 | |
| SCHEMBL27031231 | 0.85 | PIM1 (0.40) | DDB1CRBNBCHEACHESLC6A4 | |
| SCHEMBL27031202 | 0.84 | DDB1 (0.35) | DDB1CRBNBCHEACHE | |
| SCHEMBL27031209 | 0.84 | DDB1 (0.35) | DDB1CRBNBCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276964-A1 | Benzisoxazole Derivatives and Uses thereof | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-09-04 | — | — | US | disclosed |
| EP-4308559-A1 | BENZISOXAZOLE DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-01-24 | — | — | EP | disclosed |
| CN-116940571-A | Benzisoxazole derivative and use thereof | 诺华股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| WO-2022195355-A1 | BENZISOXAZOLE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276964-A1 | Benzisoxazole Derivatives and Uses thereof | HBZ, ZFX, WIZ | DDB1 1526/4885CRBN 820/4885BCHE 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.